Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 70 Years Old) With Partial Onset Seizures

X
Trial Profile

A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 70 Years Old) With Partial Onset Seizures

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brivaracetam (Primary)
  • Indications Partial epilepsies; Seizures
  • Focus Registrational; Therapeutic Use
  • Acronyms POS Phase 3
  • Sponsors UCB; UCB Pharma SA
  • Most Recent Events

    • 17 May 2022 Results of pooled post hoc (N01252/NCT00490035, N01253/NCT00464269, and N01358/NCT01261325 studies) analysis published in the Epilepsia
    • 26 Apr 2022 Results of post hoc analysis of 3 phase III trials (N01252 [NCT00490035], N01253 [NCT00464269], N01358 [NCT01261325]) assessing the time-course of treatment-emergent adverse events (TEAEs) potentially associated with behavioral disorders (BAEs) in adults with focal seizures during adjunctive brivaracetam (BRV) treatment presented at the 74th Annual Meeting of the American Academy of Neurology 2022
    • 01 Sep 2021 Results of post-hoc analysis of 3 studies (N01252/NCT00490035, N01253/NCT004642 69, N01358/NCT01261325) assessing tolerability and efficacy of brivaracetam (BRV) in patients on 1 or 2 concomitant antiepileptic drugs (AEDs) and in patients on 1 specific concomitant AED, presented at the 34th International Epilepsy Congress.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top